276863-95-7Relevant academic research and scientific papers
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment
Liu, Wenwen,Wang, Huan,Li, Xiaokang,Xu, Yixiang,Zhang, Jian,Wang, Wei,Gong, Qi,Qiu, Xiaoxia,Zhu, Jin,Mao, Fei,Zhang, Haiyan,Li, Jian
supporting information, p. 3117 - 3125 (2018/05/16)
Depression, a severe mental disease, is greatly difficult to treat and easy to induce other neuropsychiatric symptoms, the most frequent one is cognitive impairment. In this study, a series of novel vilazodone-tacrine hybrids were designed, synthesized and evaluated as multitarget agents against depression with cognitive impairment. Most compounds exhibited good multitarget activities and appropriate blood-brain barrier permeability. Specifically, compounds 1d and 2a exhibited excellent 5-HT1A agonist activities (1d, EC50 = 0.36 ± 0.08 nM; 2a, EC50 = 0.58 ± 0.14 nM) and 5-HT reuptake inhibitory activities (1d, IC50 = 20.42 ± 6.60 nM; 2a, IC50 = 22.10 ± 5.80 nM). In addition, they showed moderate ChE inhibitory activities (1d, AChE IC50 = 1.72 ± 0.217 μM, BuChE IC50 = 0.34 ± 0.03 μM; 2a, AChE IC50 = 2.36 ± 0.34 μM, BuChE IC50 = 0.10 ± 0.01 μM). Good multitarget activities with goodt blood-brain barrier permeability of 1d and 2a make them good lead compounds for the further study of depression with cognitive impairment.
Substituted indole compound and method and use thereof
-
Paragraph 0371; 0373; 0374, (2018/11/03)
The invention provides a new indole compound, pharmaceutically acceptable salts and medicinal preparations thereof, and a use of the new indole compound in selective inhibition of 5-hydroxytryptamine reuptake and /or excitation of a 5-HT1A receptor. The invention also relates to medicinal compositions comprising the compounds, and a method for treating the central nervous system dysfunction of mammals, especially humans by using the medicinal compositions.
Substituted indole compounds, as well as using method and application thereof
-
Paragraph 0144; 0194; 0195; 0196, (2017/08/02)
The invention relates to substituted indole compounds, a using method and application of the substituted indole compounds, as well as a medicine composition including the compounds and application thereof. The compounds or medicine composition can be used for inhibiting reuptake of 5-hydroxytryptamine. The invention further relates to a method for preparing the compounds and the medicine composition, as well as application of the compounds and medicine composition in treatment of central nervous system dysfunction.
Preparation method of substituted indoles compounds
-
Paragraph 0015; 0016, (2016/10/07)
The invention belongs to the field of medical technology, and discloses a preparation method of 3-substituted indoles compounds. The preparation method includes using a compound represented by formula (2) as an initial raw material, performing a Friedel-Crafts reaction with 4-chlorobutyryl chloride in the presence of anhydrous titanium tetrachloride catalyst to obtain a compound represented by formula (3), and performing a reaction with paratoluensulfonyl chloride in the presence of an organic solvent and an acid-binding agent to obtain the target compound. The preparation method overcomes the defects of the synthetic method in the prior art, and is suitable for the industrial production. The product has high content, and the purity of the product reaches over 99%.
For the preparation of the compounds and intermediates thereof the vera assists the alkone and application
-
Paragraph 0064-0068, (2017/03/24)
The invention belongs to the field of medicinal chemistry and relates to a compound for preparing vilazodone as well as an intermediate and an application thereof. The compound for preparing vilazodone is shown as a formula I, and the intermediate for synthesizing the compound of the formula I is shown as a formula II. The compound of the formula I can be applied to preparation of vilazodone and pharmaceutically acceptable salts thereof. The compound of the formula I serving as a novel intermediate is applied in preparation of the vilazodone, the defects in the conventional literature report are overcome, metal catalysts with high toxicity and organic phosphorus ligands thereof are avoided, the preparation cost is greatly reduced, the operation is simplified, and the compound is stable and controllable in quality and suitable for large-scale industrial preparation.
SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS OF USE AND USE THEREOF
-
Page/Page column 49, (2016/12/22)
The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.
Intermediate the vera assists the alkone 5-cyano -3 (4-chlorobutyl)-indole new synthetic process
-
Paragraph 0020; 0021, (2017/02/09)
The invention discloses a new synthetic process of a vilazodone intermediate 5-cyano-3(4-chlorobutyl)-indole. The synthetic process comprises the steps of enabling 5-amino-formyl-indole and 4-chlorobutyryl chloride undergo a 3-bit acylation reaction and a dehydration reaction of an amido bond in the presence of a catalyst to produce 5-bit cyan, then performing a decarbonylation reaction in the presence of a reducing agent to generate a product, and finally refining by the product by use of methanol to obtain high-purity high-content 5-cyano-3(4-chlorobutyl)-indole. The process is concise, simple to operate and applicable to large-scale industrial production.
SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
-
Paragraph 00203, (2015/02/25)
Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are pharmaceutical compositions comprising the heteroaryl compounds and methods of using the pharmaceutical compositions in treating central nervous system (CNS) dysfunction in a mammal, especially a human being.
SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS AND USE THEREOF
-
Paragraph 00232, (2015/11/27)
Provided herein are novel piperazine compounds acting as selective serotonin reuptake inhibitors and/or the 5-HT1A receptor agonists. The invention also relates to the methods of preparing the compound and pharmaceutical composition, and the use of treating central nervous system dysfunction in mammals especially in humans.
PROCESS FOR THE PREPARATION OF VILAZODONE HYDROCHLORIDE AND ITS AMORPHOUS FORM
-
Paragraph 0093, (2015/03/31)
The present invention relates to an improved process for the preparation of vilazodone Hydrochloride and a process for preparation of novel pure amorphous form of vilazodone hydrochloride.

